HHC vs Delta-8: How the Two Semi-Synthetic Cannabinoids Compare

HHC (hexahydrocannabinol) is a hydrogenated form of THC with no double bond in its ring, while delta-8 is a THC isomer with the double bond moved. Both are usually made from hemp CBD. Delta-8 is less potent than delta-9 in controlled trials; HHC has only one tiny human study, which found effects comparable to THC. Potency varies because HHC comes as two forms in unpredictable ratios.

Pages ranking for this comparison tend to place HHC neatly “between delta-8 and delta-9” and say it may not show up on drug tests. Neither claim holds up well. The human data on HHC are extremely thin, cell studies suggest one form of HHC activates the CB1 receptor at least as strongly as delta-9, and HHC metabolites can trigger standard urine screens.

Below we compare how each is made, what has been measured, the safety and testing picture, and what the federal hemp redefinition means for both. For background, see our glossary entries on HHC and delta-8 THC.

At a glance

Property	HHC	Delta-8 THC
Chemical type	Hydrogenated THC, no ring double bond	THC isomer, double bond at carbon 8
How it is made	CBD converted to delta-8/delta-9, then hydrogenated1	Acid-catalysed conversion of hemp CBD
Forms in products	Mix of 9(R) and 9(S) epimers; ratio varies by batch2	Single main compound, plus conversion by-products
Relative potency	Uncertain; 9(R) form is THC-like, 9(S) weaker	Less potent than delta-9 per milligram5
Human studies	One pilot study, three people per route3	Two controlled crossover trials (2025)
Drug test	Metabolites can cross-react with urine screens8	Metabolites trigger standard urine screens8
US federal status	Loses hemp status by 11 December 2026 at latest	Loses hemp status on 11 December 2026
UK status	Advised for Class B; supply already restricted12	Class B controlled drug

What HHC and delta-8 are, and how each is made

Delta-8 THC is an isomer of delta-9: the same atoms, with one double bond in a different position. It occurs naturally only in trace amounts, so commercial delta-8 is made by treating hemp-derived CBD with acid and heat, a process covered in our entry on cannabinoid conversion.

HHC goes one step further. A 2024 review describes the standard industrial route: CBD is first cyclised into a mixture of delta-8 and delta-9 THC, and that mixture is then hydrogenated with a catalyst, adding hydrogen atoms across the remaining double bond.¹ The “hexahydro” in the name refers to those extra hydrogens. HHC was first synthesised around eight decades ago, but only appeared on the drug market in 2021.

One reaction separates the two, and it matters. Hydrogenation creates a new chiral centre, so HHC always comes as two epimers, 9(R)-HHC and 9(S)-HHC. They are not equal. Preclinical studies suggest the 9(R) form has THC-like activity, while the 9(S) form is weaker.¹ Analysis of seized products found the ratio between the two varied from batch to batch.²

Potency and effects: what has actually been measured

Delta-8 has the better-characterised profile. A review of its pharmacology found it is a partial agonist at the CB1 receptor with weaker affinity than delta-9, which explains its lower potency.⁴ In a 2025 double-blind trial in 19 healthy adults, 20 mg of oral delta-8 produced weaker effects and less impairment than 20 mg of delta-9, but 40 mg of delta-8 was indistinguishable from 20 mg of delta-9.⁵

For HHC, the picture is murkier. In a cell-based assay of 30 THC-related compounds, HHC was among those showing a higher potential to activate CB1 than delta-9 on at least one measure, either maximum effect or potency.² The same study found that batches richer in 9(S)-HHC were less potent, though still active.

The only controlled human data come from a small pilot study: three people ate a 25 mg HHC gummy and three took three puffs from an HHC vape. Pharmacokinetics and effects were broadly comparable to THC, with large differences between individuals and routes.³ Six people is not enough to rank HHC against delta-8 or delta-9.

So the common claim that HHC sits “between delta-8 and delta-9” is a guess. Given the variable epimer ratio, two HHC products with the same milligram label could feel quite different.

How strong is the evidence?

• Delta-8: decades of preclinical work, two small but well-designed human trials published in 2025, and several years of poison centre and adverse event data. Reasonable for short-term effects; weak for long-term use.
• HHC: older animal studies, recent cell assays and one six-person pilot study. The 2024 review notes that human pharmacology and metabolism are still largely uninvestigated.¹ Very weak.

Survey data give some sense of real-world use. In an online survey of 229 US adults who used cannabis, published in 2026, 21.8% reported past-year delta-8 use and 3.5% reported HHC use; adverse effects were reported for every semi-synthetic cannabinoid covered.⁶ Surveys like this are self-selected and cannot establish which compound is safer.

What none of the evidence supports is the idea that either compound is a gentle or low-risk alternative to cannabis. Both are intoxicating, both are produced by chemistry that can leave by-products, and neither is made under pharmaceutical quality controls.

Safety, side effects and drug testing

Reported side effects for both overlap with cannabis intoxication: anxiety, paranoia, a fast heart rate, dizziness, drowsiness and impaired coordination. Edibles carry the added risk of delayed onset, which can lead people to take a second dose too soon. Children who find gummies are a recurring concern in poison centre data.

Product strength is a real problem. Forensic chemists who analysed synthetically derived THC products between 2019 and 2024 found gummies containing 57 to 321 mg of total THC isomers each, and one THC and HHC combination gummy containing 791 mg of combined THC and HHC isomers.⁷ At those amounts, a single piece can exceed a cautious dose many times over.

Will HHC show up on a drug test?

Sellers sometimes suggest HHC is invisible to drug tests. That is not a safe assumption. A study of six widely used urine immunoassays found that HHC carboxylic acid metabolites cross-reacted with the screens, as did delta-8 metabolites, with sensitivity depending on the kit and cutoff.⁸ The pilot study also examined immunological detection of HHC.³ Confirmation testing can identify HHC specifically.

Anyone who is subject to testing, drives, takes prescription medicines, or is pregnant or breastfeeding should treat both compounds as they would THC.

Legal status in September 2026

Both compounds spread through the gap in the 2018 Farm Bill, which defined hemp by its delta-9 THC content alone. That gap is closing, and the timing is now split across two dates.

Section 781 of Public Law 119-37, enacted on 12 November 2025, redefines hemp from 12 November 2026.⁹ It measures total THC (including THCA) rather than delta-9 alone, and excludes finished products that contain:

• cannabinoids “not capable of being naturally produced” by the cannabis plant;
• naturally occurring cannabinoids that were synthesised or manufactured outside the plant; or
• more than 0.4 mg per container of total THC plus other cannabinoids with similar effects.

A September 2026 law (H.R. 6500, section 2019) limits what applies before 11 December 2026 to the first exclusion only. The total THC test, the “manufactured outside the plant” exclusion and the 0.4 mg cap start on 11 December.¹⁰

For delta-8, which occurs naturally in trace amounts, that points to 11 December. HHC is less certain: if it is treated as not naturally producible, it could lose hemp status on 12 November. The FDA was required to publish lists settling these questions, but as of August 2026 it had not.¹¹ In practice, HHC made by hydrogenating converted CBD is manufactured outside the plant, and typical products far exceed 0.4 mg per container, so both lose hemp status by 11 December at the latest. Bills to delay or repeal the change are in committee but none had been scheduled for a vote. State rules vary and often go further; see our delta-8 state law guide.

UK: delta-8 is a Class B drug. In May 2025 the Advisory Council on the Misuse of Drugs recommended Class B control for HHC and noted that, until then, psychoactive examples fall under the Psychoactive Substances Act 2016.¹² Canada: delta-8 is regulated as cannabis under the Cannabis Act and may be sold only through licensed channels. We found no specific Health Canada guidance on HHC, so treat unlicensed HHC products as outside the legal market.

What to check before buying, where sale is still legal

If you live somewhere these products remain on sale, the certificate of analysis is your main safeguard. Our guide to the hemp COA explains how to read one. For HHC and delta-8, check:

• Epimer breakdown for HHC. A COA that reports 9(R)-HHC and 9(S)-HHC separately tells you far more than a single “HHC” figure, because the ratio affects potency.²
• Delta-9 and total THC. Both compounds start from a delta-8/delta-9 mixture or are made alongside delta-9, so residual delta-9 is possible.
• Milligrams per piece and per pack. Very high-strength gummies exist.⁷ From 11 December 2026 the federal hemp limit is 0.4 mg of total THC and similar cannabinoids per container.
• Heavy metals and residual solvents. HHC production uses a metal catalyst, and both processes use solvents and acids.
• Batch match and accreditation. The COA batch should match the pack, from an ISO/IEC 17025 accredited lab.

For how delta-8 compares with other hemp-derived THC products, see our comparison of delta-8, delta-9 and THC-O.

Frequently asked questions

Is HHC stronger than delta-8?

It may be, but the evidence is too thin to say by how much. Delta-8 is less potent than delta-9 in controlled trials.⁵ HHC’s 9(R) form is THC-like in lab studies and one cell assay found HHC activated CB1 as strongly as delta-9 on some measures.² Because products mix 9(R) and 9(S) in varying ratios, strength can differ between batches.

Does HHC show up on a drug test?

It can. HHC carboxylic acid metabolites cross-reacted with several standard urine cannabinoid immunoassays in a laboratory study, depending on the kit and cutoff.⁸ Forensic labs can also confirm HHC specifically. Claims that HHC is undetectable should not be relied on by anyone who is drug tested.

Is HHC natural or synthetic?

Commercial HHC is semi-synthetic. It is made by converting hemp CBD into a delta-8 and delta-9 mixture and then hydrogenating it with a catalyst.¹ Delta-8 on the market is also produced by chemical conversion, though delta-8 itself occurs in small amounts in the plant. Neither is simply extracted from hemp.

Is HHC legal in 2026?

Under US federal law, HHC products lose hemp status by 11 December 2026 at the latest, and possibly from 12 November if HHC is treated as not naturally producible.¹⁰ Many states already restrict it. In the UK, supply is restricted under the Psychoactive Substances Act and Class B control has been recommended.¹²

Is HHC safer than delta-8?

There is no evidence that it is. HHC has far less human research than delta-8, adds a hydrogenation step to the manufacturing chain, and comes in variable epimer ratios that make dosing less predictable. Both compounds cause intoxication and share the risks of cannabis, including impaired driving and accidental ingestion by children.

Sources

1. Ujváry I. Hexahydrocannabinol and closely related semi-synthetic cannabinoids: A comprehensive review. Drug Test Anal. 2024;16(2):127-161. DOI: 10.1002/dta.3519. PMID: 37269160. pubmed.ncbi.nlm.nih.gov
2. Janssens LK, Van Uytfanghe K, Williams JB, Hering KW, Iula DM, Stove CP. Investigation of the intrinsic cannabinoid activity of hemp-derived and semisynthetic cannabinoids with β-arrestin2 recruitment assays-and how this matters for the harm potential of seized drugs. Arch Toxicol. 2024;98(8):2619-2630. DOI: 10.1007/s00204-024-03769-4. PMID: 38735004. pubmed.ncbi.nlm.nih.gov
3. Höfert L, Franz B, Groß C, et al.. Preliminary pharmacokinetic and psychophysical investigations after controlled oral and inhalative consumption of hexahydrocannabinol (HHC). Sci Rep. 2025;15(1):10086. DOI: 10.1038/s41598-025-93931-4. PMID: 40128283. pubmed.ncbi.nlm.nih.gov
4. Tagen M, Klumpers LE. Review of delta-8-tetrahydrocannabinol (Δ8-THC): Comparative pharmacology with Δ9-THC. Br J Pharmacol. 2022;179(15):3915-3933. DOI: 10.1111/bph.15865. PMID: 35523678. pubmed.ncbi.nlm.nih.gov
5. Zamarripa CA, Spindle TR, Schriefer D, et al.. A within-subject cross-over trial comparing the acute effects of oral delta-8-tetrahydrocannabinol and delta-9-tetrahydrocannabinol in healthy adults. Drug Alcohol Depend. 2025;272:112676. DOI: 10.1016/j.drugalcdep.2025.112676. PMID: 40288059. pubmed.ncbi.nlm.nih.gov
6. Pabon E, Lake S, Murray CH, Cooper ZD. Emerging Hemp-Derived Semi-Synthetic Cannabinoids, Absent Regulations: Patterns of Use and Adverse Effects Among a Sample of U.S. Cannabis Consumers. Cannabis Cannabinoid Res. 2026;11(5):396-404. DOI: 10.1177/25785125251391987. PMID: 41335500. pubmed.ncbi.nlm.nih.gov
7. Ciolino LA, Ranieri TL. HPLC-UV quantitation of synthetically derived THC, THCP, and HHC isomers in commercial vaping liquids and edibles (2019-2024). J Forensic Sci. 2026 (online ahead of print). DOI: 10.1111/1556-4029.70408. PMID: 42748050. pubmed.ncbi.nlm.nih.gov
8. Wolf CE, Pokhai AA, Poklis JL, Williams GR. The cross-reactivity of cannabinoid analogs (delta-8-THC, delta-10-THC and CBD), their metabolites and chiral carboxy HHC metabolites in urine of six commercially available homogeneous immunoassays. J Anal Toxicol. 2023;47(8):732-736. PMID: 37602947. pubmed.ncbi.nlm.nih.gov
9. U.S. Congress. Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026. Public Law 119-37 (H.R. 5371), Division B, Section 781, amending section 297A of the Agricultural Marketing Act of 1946 (7 U.S.C. 1639o). Enacted 12 November 2025. govinfo.gov
10. U.S. Congress. Continuing Appropriations and Extensions Act, 2027. H.R. 6500 (enrolled bill), Section 2019, “Section 781 Extension”. 2026. govinfo.gov
11. Congressional Research Service. Changes to the Statutory Definition of Hemp and Implications for Agricultural Policy. In Focus IF13136. Updated August 2026. congress.gov
12. Advisory Council on the Misuse of Drugs. ‘Semi-synthetic’ Cannabinoids: Cannabinoids related to tetrahydrocannabinol and cannabidiol. Report and cover letter to the Minister of State, 22 May 2025. gov.uk

Editorial note: This article is for general information only and is not medical or legal advice. HHC and delta-8 THC have not been evaluated by the FDA to diagnose, treat, cure or prevent any disease. Laws vary by location and change often, so verify the rules that apply where you are. Always talk to a licensed healthcare provider before use, especially if you are under 21, pregnant or nursing, taking medication, or managing a health condition.